Differential Induction of Peroxisomal Enzymes by Hypolipidaemics in Human (HepG2) and Rat (MH1C1) Hepatoma Cell Lines
- 1 January 1995
- journal article
- research article
- Published by Walter de Gruyter GmbH in cclm
- Vol. 33 (11) , 775-784
- https://doi.org/10.1515/cclm.1995.33.11.775
Abstract
Human (HepG2) and rat (MH1C1) hepatoblastoma cells were incubated with different concentrations of the hypolipidaemics cetaben, clofibrate and thyroxine. The enzymatic activities of catalase, peroxisomal bifunctional enzyme, succinate dehydrogenase, and 3-oxoacyl-CoA thiolase were measured. In order to determine the point of regulation of the enzymatic activities Northern and Slot blot experiments with probes for peroxisomal bifunctional enzyme, catalase and fatty acyl CoA oxidase were performed on total RNA. Catalase activity was enhanced in HepG2 cells treated with 3 mmol/l clofibric acid to 135% of control and the mRNA value to 2.6 fold, whereas in cetaben treated cells the enhancement (up to 119% of control) was less pronounced. In MH1C1 cells catalase activity was not changed by any of the drugs. The activity of the peroxisomal bifunctional enzyme was not affected in HepG2 cells by clofibric acid and cetaben, whereas the mRNA level was elevated to 2.3 fold by 10 micromol/l cetaben. At high concentrations of cetaben all enzyme activities were decreased in both cell lines due to its high cytotoxicity. Our data show that, due to the differences in the genomic organisation, the regulation of the enzyme activities is different in human and rat, but the results from the human and rat hepatoblastoma cells correlate with the findings in whole man and rat, so that a human in vitro system is more suitable for pharmacological tests. These results suggest that the human hepatoma cell line HepG2 may be a useful model system for studies of the influence of hypolipidaemics on the peroxisomal enzyme system.Keywords
This publication has 31 references indexed in Scilit:
- Modulation of thyroid hormone action by mutant thyroid hormone receptors, c-erbAα2 and peroxisome proliferator-activated receptor: evidence for different mechanisms of inhibitionMolecular and Cellular Endocrinology, 1995
- Lack of Peroxisome Proliferation in Marmoset Liver Following Treatment with Ciprofibrate for 3 YearsFundamental and Applied Toxicology, 1994
- cDNA Cloning of the Human Peroxisomal Enoyl-CoA Hydratase: 3-Hydroxyacyl-CoA Dehydrogenase Bifunctional Enzyme and Localization to Chromosome 3q26.3-3q28: A Free Left Alu Arm Is Inserted in the 3′ Noncoding RegionGenomics, 1994
- Stimulation of peroxisomal palmitoyl‐CoA oxidase activity by ciprofibrate in hepatic cell lines: Comparative studies in Fao, MH1C1 and HepG2 cellsBiology of the Cell, 1993
- BIOCHEMISTRY OF PEROXISOMESAnnual Review of Biochemistry, 1992
- Mechanisms of Lipid-Lowering AgentsCardiology, 1991
- An in vitro demonstration of peroxisome proliferation and increase in peroxisomal β‐oxidation system mRNAs in cultured rat hepatocytes treated with ciprofibrateFEBS Letters, 1989
- The Effect of Peroxisome Prouferators on Microsomal. Peroxisomal, and Mitochondrial Enzyme Activities in the Liver and KidneyDrug Metabolism Reviews, 1987
- Number and organization of actin-related sequences in the mouse genomeJournal of Molecular Biology, 1983
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976